The proportion cured of patients diagnosed with stage III-IV cutaneous malignant melanoma in Sweden 1990-2007: A population-based study

Abstract

The survival in cutaneous malignant melanoma (CMM) is highly dependent on the stage of the disease. Stage III-IV CMM patients are at high risk of relapse with a heterogeneous outcome, but not all experience excess mortality due to their disease. This group is referred to as the cure proportion representing the proportion of patients who experience the same mortality rate as the general population. The aim of this study was to estimate the cure proportion of patients diagnosed with stage III-IV CMM in Sweden. From the population-based Swedish Melanoma Register, we included 856 patients diagnosed with primary stage III-IV CMM, 1990-2007, followed-up through 2013. We used flexible parametric cure models to estimate cure proportions and median survival times (MSTs) of uncured by sex, age, tumor site, ulceration status (in stage III patients) and clinical stage. The standardized (over sex, age and site) cure proportion was lower in stage IV CMMs (0.15, 95% CI 0.09-0.22) than non-ulcerated stage III CMMs (0.48, 95% CI 0.41-0.55) with a statistically significant difference of 0.33 (95% CI=0.24-0.41). Ulcerated stage III CMMs had a cure proportion of 0.27 (95% CI 0.21-0.32) with a statistically significant difference compared to non-ulcerated stage III CMMs (difference 0.21; 95% CI=0.13-0.30). The standardized MST of uncured was approximately 9-10 months longer for non-ulcerated vs. ulcerated stage III CMMs. We could demonstrate a significantly better outcome in patients diagnosed with non-ulcerated stage III CMMs compared to ulcerated stage III CMMs and stage IV disease after adjusting for age, sex and tumor site. This article is protected by copyright. All rights reserved.

from Cancer via ola Kala on Inoreader http://ift.tt/1SL2Iq7
via IFTTT